iTeos Therapeutics

iTeos Therapeutics

  • Founded: 2011
  • Location: Watertown, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin2
  • Therapy area: Solid tumors
  • Drug types: ONC
  • Lead product: Inupadenant
  • Product link:
  • Funding: $231M IPO Jul 2020; $100M B-2 Mar 2020; €15M Jan 2020; $75M B Jun 2018

job board

Short description:

Cancer Immunotherapy

Drug notes:

Also Clin2 NSCLC; EOS-448 6 trials Clin1/Clin2 multiple cancers; EOS-984 Clin0 oncology

Long description:

iTeos Therapeutics is developing next-generation immuno-oncology therapies to fight cancer. iTeos' platform is designed to identify and develop therapies that can activate and modulate the immune system to recognize and attack cancer cells. The company's therapies overcome the limitations of traditional immuno-oncology therapies, such as: limited efficacy (iTeos' therapies target multiple immune checkpoints and activate multiple immune cell types) and autoimmune side effects (iTeos' therapies are less toxic by targeting specific immune checkpoints and activating immune cells in a controlled manner).The company's lead product candidate is an anti-PD-1 and anti-TIGIT combination therapy for the treatment of non-small cell lung cancer.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy